We co-incubated either unstimulated or GM-CSF stimulated neutrophils with neuroblastoma cell lines IMR-32 and NMB in the presence or absence of the therapeutic antibody dinutuximab, which binds to GD2, a target on this tumor type (Figure 3H and Suppl. Here, CSF2 is linked to neuroblastoma.